PMV Pharmaceuticals Reports Q3 GAAP EPS of -$0.52, Missing Estimates by $0.18
PMV Pharmaceuticals (PMVP) reported third-quarter financial results featuring a GAAP earnings per share (EPS) of -$0.52. This figure represents a miss of $0.18 relative to market expectations. The company continues to focus on its clinical mission regarding the restoration of mutant P53 for cancer treatment. As of September 30, 2026, the company reported holding $108.5 million in cash, cash equivalents, and marketable securities. This liquidity position is critical as the firm navigates its development stages following a recent $50 million IPO priced at $1.21 per share.
Tickers: $PMVP
Topics: cash position earnings report GAAP EPS